Loading ...maybe they should test for CRP instead of wasting billions on statins
“The new drug is called canakinumab (brand name Ilaris), and it decreases inflammation as measured by a blood test called hsCRP (highly sensitive C-reactive protein). Ilaris was given to 10,000 heart attack survivors who were already on a statin and had normal cholesterol, but elevated hsCRPs. The patients on Ilaris were followed for four years and, compared with a placebo group, had a 15 percent lower risk of recurrent heart attacks and strokes, and “surprisingly a lower rate of cancer.”